Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT03093701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03093701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Lead sponsor
Taiwan Liposome Company
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2017
Completion date
February 4, 2019
Enrollment
31 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

macula edema, retinal vein occlusion